How to buy Infinity Pharmaceuticals stock | $3.33

Infinity Pharmaceuticals, Inc is a biotechnology business based in the US. Infinity Pharmaceuticals shares (INFI) are listed on the NASDAQ and all prices are listed in US Dollars. Infinity Pharmaceuticals employs 23 staff and has a trailing 12-month revenue of around 0.00.

Infinity Pharmaceuticals stock price (NASDAQ: INFI)

Use our graph to track the performance of INFI stocks over time.

Infinity Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$3.33
52-week range	$0.88 - $5.98
50-day moving average	$2.86
200-day moving average	$3.20
Wall St. target price	$8.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.34

Buy Infinity Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Infinity Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Infinity Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Infinity Pharmaceuticals price performance over time

Historical closes compared with the close of $3.33 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	16.43%
3 months (2021-05-03)	-0.60%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Infinity Pharmaceuticals financials

Revenue TTM	$1.9 million
Gross profit TTM	$-26,079,000
Return on assets TTM	-34.64%
Return on equity TTM	-285.39%
Profit margin	0%
Book value	$0.47
Market capitalisation	$188.1 million

TTM: trailing 12 months

Shorting Infinity Pharmaceuticals shares

There are currently 4.4 million Infinity Pharmaceuticals shares held short by investors – that's known as Infinity Pharmaceuticals's "short interest". This figure is 19% down from 5.5 million last month.

There are a few different ways that this level of interest in shorting Infinity Pharmaceuticals shares can be evaluated.

Infinity Pharmaceuticals's "short interest ratio" (SIR)

Infinity Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Infinity Pharmaceuticals shares currently shorted divided by the average quantity of Infinity Pharmaceuticals shares traded daily (recently around 2.7 million). Infinity Pharmaceuticals's SIR currently stands at 1.67. In other words for every 100,000 Infinity Pharmaceuticals shares traded daily on the market, roughly 1670 shares are currently held short.

However Infinity Pharmaceuticals's short interest can also be evaluated against the total number of Infinity Pharmaceuticals shares, or, against the total number of tradable Infinity Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Infinity Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Infinity Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0617% of the tradable shares (for every 100,000 tradable Infinity Pharmaceuticals shares, roughly 62 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Infinity Pharmaceuticals.

Find out more about how you can short Infinity Pharmaceuticals stock.

Infinity Pharmaceuticals share dividends

We're not expecting Infinity Pharmaceuticals to pay a dividend over the next 12 months.

Have Infinity Pharmaceuticals's shares ever split?

Infinity Pharmaceuticals's shares were split on a 1:4 basis on 12 September 2006. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Infinity Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Infinity Pharmaceuticals shares which in turn could have impacted Infinity Pharmaceuticals's share price.

Infinity Pharmaceuticals share price volatility

Over the last 12 months, Infinity Pharmaceuticals's shares have ranged in value from as little as $0.8756 up to $5.98. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Infinity Pharmaceuticals's is 2.1937. This would suggest that Infinity Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Infinity Pharmaceuticals overview

Infinity Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc.

Frequently asked questions

What percentage of Infinity Pharmaceuticals is owned by insiders or institutions?
Currently 2.173% of Infinity Pharmaceuticals shares are held by insiders and 58.477% by institutions. How many people work for Infinity Pharmaceuticals?
Latest data suggests 23 work at Infinity Pharmaceuticals. When does the fiscal year end for Infinity Pharmaceuticals?
Infinity Pharmaceuticals's fiscal year ends in December. Where is Infinity Pharmaceuticals based?
Infinity Pharmaceuticals's address is: 1100 Massachusetts Avenue, Cambridge, MA, United States, 02138 What is Infinity Pharmaceuticals's ISIN number?
Infinity Pharmaceuticals's international securities identification number is: US45665G3039 What is Infinity Pharmaceuticals's CUSIP number?
Infinity Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 254675101